Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28078662 | 0.77 | KDM4E (0.32) | LMNA | |
| SCHEMBL6627458 | 0.77 | SLC18A3 (0.37) | LMNACSNK2A1 | |
| SCHEMBL7126010 | 0.73 | KDM4E (0.31) | — | |
| SCHEMBL7350683 | 0.72 | TSHR (0.35) | — | |
| SCHEMBL13810692 | 0.72 | MAPT (0.39) | MAPTLMNAALDH1A1 | |
| SCHEMBL7991895 | 0.70 | — | — | |
| SCHEMBL23540099 | 0.70 | TSHR (0.53) | MAPTATMALDH1A1 | |
| SCHEMBL11292777 | 0.70 | AGER (0.53) | — | |
| SCHEMBL7147178 | 0.70 | TSHR (0.53) | MAPTATMALDH1A1 | |
| SCHEMBL10730735 | 0.70 | AGER (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032669-B | Orthoester compositions for affinity purification of oligonucleotides | 安捷伦科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230122968-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11548876-B2 | Orthoester compositions for affinity purification of oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548876-B2 | Orthoester compositions for affinity purification of oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11299483-B2 | Orthoester compositions for affinity purification of oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20200190129-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190129-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200181124-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2020-06-11 | — | — | US | disclosed |
| US-7179581-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179581-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | COOK PHILLIP D (US) | 2003-04-03 | — | — | US | disclosed |
| US-6448373-B1 | INHIBITORS OF ENZYMES SUCH AS PHOSPHOLIPASE A2; TREATMENT OF INFLAMMATORY DISEASES INCLUDING ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASE | ISIS PHARMACEUTICALS, INC. | 2002-09-10 | — | — | US | disclosed |
| EP-0739351-B1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-5886177-A | ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0739351-A4 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0739351-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190129-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | MAPT 1562/4885ATM 1026/4885LMNA 3111/4885 |
| US-20230122968-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, DCLRE1B, MRTO4 | MAPT 1375/4885ATM 993/4885LMNA 3109/4885 |
| US-20200181124-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | MAPT 1562/4885ATM 1026/4885LMNA 3111/4885 |
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | BPGM, PPIP5K2, PGM2 | MAPT 1278/4885ATM 4022/4885LMNA 2734/4885 |
| US-11548876-B2 | Orthoester compositions for affinity purification of oligonucleotides | RNGTT, OSBPL8, DCLRE1B | MAPT 1562/4885ATM 1026/4885LMNA 3111/4885 |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | MAPT 1562/4885ATM 1026/4885LMNA 3111/4885 |
| US-11299483-B2 | Orthoester compositions for affinity purification of oligonucleotides | RNGTT, OSBPL8, DCLRE1B | MAPT 1562/4885ATM 1026/4885LMNA 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.